Immediate Impact
60 standout
Citing Papers
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Standout
Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes
2025 Standout
Works of Hannah Bye being referenced
PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.
2019
PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Hannah Bye | 75 | 53 | 43 | 14 | 160 | |
| Haobo Li | 97 | 70 | 25 | 11 | 183 | |
| David Papadimos | 62 | 69 | 38 | 11 | 203 | |
| Sarah A. McGarrigle | 92 | 46 | 64 | 16 | 238 | |
| Jiashuo Chao | 65 | 38 | 52 | 19 | 218 | |
| Elvira Stacher‐Priehse | 100 | 101 | 24 | 14 | 214 | |
| Guochun Cao | 57 | 30 | 41 | 18 | 138 | |
| Carolina Conte | 109 | 47 | 23 | 10 | 237 | |
| Marilena Melas | 67 | 20 | 19 | 15 | 145 | |
| Nur Sabrina Sapari | 108 | 47 | 31 | 15 | 194 | |
| Taiying Lu | 96 | 15 | 16 | 21 | 167 |
All Works
Loading papers...